We’re proud to announce we have secured a Special Protocol Assessment agreement from the FDA for our planned Phase 3 non-proliferative diabetic retinopathy (NPDR) trial, a significant step in our mission to redefine the retina experience.​ Learn more: https://t.co/gXPMKeJBhM

Catch up with our team at the @aao_ophth Annual Meeting this week in Orlando. ​ Excited to share how we’re working to redefine treatments for patients with retinal disease, including wet age-related macular degeneration. ​ #AAO2025 #RetinaRedefined

Looking forward to an impactful series of meetings as Innovate Retina, @Eyecelerator, and @aao_ophth showcase advances in retina care. Joining these events reinforces our commitment to redefining the retina experience. Learn more: https://t.co/HmpleiYISU #RetinaRedefined

Thank you to everyone who attended our Investor Day and joined us for an exciting discussion on Ocular's progress. We shared updates on our clinical trials and their potential to impact patients. Check out the highlights: https://t.co/JFgRvRfe1m #RetinaRedefined

Proud to attend @RetinaSociety’s annual meeting and support their mission of reducing worldwide visual disability and blindness. We enjoyed the meaningful conversations and forums as we advance our mission to redefine the retina experience. #TheRetinaSociety #RetinaRedefined

Reflecting on an insightful week of innovation across EIS, OFF, and @EURETINA, where we connected with industry leaders and deepened our commitment to redefining the retina experience. Grateful for the momentum as we work to transform retinal disease treatment. #RetinaRedefined

Reminder that Ocular's Investor Day is on September 30 in New York City. We'll share key updates on our clinical trials for retinal as we progress our mission to redefine the retina experience. Learn more: https://t.co/RHNVxZfUiI #RetinaRedefined

We’re gearing up for key retina events where our team will discuss the future of retina disease treatments and connect with colleagues as we continue advancing our mission to redefine the retina experience. Learn more: https://t.co/cmipmijs4L #EURETINA2025 #RetinaSociety

We’re excited to join the @MorganStanley and @rwbaird Healthcare Conferences to explore how innovation and patient experience intersect as we work to redefine the retina experience. Learn more: https://t.co/cmipmijs4L #RetinaRedefined

Attending @WIO2025 offered a valuable opportunity to connect with dynamic female leaders who are working to move retina care forward.   Our discussions reaffirm the importance of our work at Ocular as we aim to redefine the retina experience. #WIO2025 #RetinaRedefined

That’s a wrap on @asrsdocs 2025! We appreciated the opportunity to share updates from our HELIOS trial in diabetic retinopathy and highlight our mission to redefine the retina experience – and we’re excited for what’s ahead. #ASRS2025 #RetinaRedefined

Our team is looking forward to hosting an Investor Day on September 30. Hear updates from senior leadership and key opinion leaders on our corporate strategy, our mission to redefine the retina experience, and more. ​ https://t.co/WQCIlLByKM #RetinaRedefined

We’ve announced our second quarter 2025 financial results. The report highlights continued progress and our commitment to redefining the retina experience. ​ Learn more: https://t.co/yNcvXLxt1i #RetinaRedefined

We’re looking forward to attending the 2025 @WIO_WomenInOpht Summer Symposium to reflect on key contributions within the ophthalmology community and support the inspiring leadership and mentorship driving the field forward. #WIO2025 #RetinaRedefined

Join us as we share our Q2 2025 earnings on August 5, where we will highlight key financial outcomes and progress made during the quarter.​ Learn more: https://t.co/3xL6s0lgv7 #RetinaRedefined

Our team is looking forward to the @asrsdocs Annual Meeting, where we’ll be presenting data from our HELIOS trial in diabetic retinopathy. Stop by Booth 201 to learn how we’re aiming to redefine the retina experience. #ASRS2025 #RetinaRedefined

We’re heading to @OISTWEETS Retina 2025, where Ocular’s Chief Strategy Officer, Sanjay Nayak, MBBS, PhD, will share a corporate update. Our team will also explore the advancements that are transforming how we see and treat retinal disease. #OISRetina #RetinaRedefined

We’re excited to attend several key retina events in the coming weeks, where we’ll share updates on our HELIOS trial as we continue on our mission to redefine the retina experience. Learn more: https://t.co/6dr0Alb8eZ #OISRetina #ASRS2025 #WIO2025

We enjoyed sharing updates from our SOL and HELIOS clinical trials at @CTS_Tahoe. Our conversations were inspiring, and we’re energized to continue working to redefine the retina experience. Thanks to everyone who made it such a memorable meeting! #CTS2025 #RetinaRedefined

We're excited for @CTS_Tahoe, where Peter Kaiser, MD, and Jeff Heier, MD, will serve as co-chairs. We’ll present updates on our SOL and HELIOS trials and discuss our mission to redefine the retina experience. Learn more: https://t.co/ztk42n8Dqo #CTS2025 #RetinaRedefined